肿瘤防治研究2012，Vol.39Issue(4)：449-451,3.DOI:10.3971/j.issn.1000-8578.2012.04.021
尼妥珠单抗联合化疗治疗转移性鼻咽癌的研究
Study of Nimotuzumab Combined with Chemotherapy Treatment for Metastatic Nasopharyngeal Carcinoma
陆颖 1黄海欣 1李桂生1
作者信息
- 1. 545005,广西柳州,广西医科大学第四附属医院肿瘤科
- 折叠
摘要
Abstract
Objective To evaluate the outcome and side-effect of nimotuzumab combined with gemcitabine chemotherapy for metastatic nasopharyngeal carcinoma. Methods Thirteen cases of metastatic nasopharyn-geal carcinoma were included in this study. All patients received nimotuzumab (200 mg/w) combined with gemcitabine( 1 000 mg/m2 ,dl ,d8) regimen therapy, 21 days was one cycle. Their clinical response was assessed after 2 cycles of chemotherapy. Results There were 2 CR cases (15. 2 % ), 6 PR cases (46. 2 % ), the total response rate( CR + PR) was 61. 5% ; 1 year survival rate was 76. 9 %. Drug related toxic effect was Ⅰ-Ⅱ grand bone narrow depression. Conclusion Nimotuzumab combined with gemcitabine has a better short-term efficacy in the treatment of patients with metastatic nasopharyngeal carcinoma,and the toxicities are acceptable.关键词
鼻咽癌/药物疗法/尼妥珠单抗/吉西他滨Key words
Nasopharyngeal carcinoma/Drug therapy/Nimotuzumab/Gemcitabine分类
医药卫生引用本文复制引用
陆颖,黄海欣,李桂生..尼妥珠单抗联合化疗治疗转移性鼻咽癌的研究[J].肿瘤防治研究,2012,39(4):449-451,3.
